These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34933182)

  • 1. LCN2 deficiency ameliorates doxorubicin-induced cardiomyopathy in mice.
    Jang HM; Lee JY; An HS; Ahn YJ; Jeong EA; Shin HJ; Kim KE; Lee J; Koh JS; Roh GS
    Biochem Biophys Res Commun; 2022 Jan; 588():8-14. PubMed ID: 34933182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipocalin-2 (NGAL) Attenuates Autophagy to Exacerbate Cardiac Apoptosis Induced by Myocardial Ischemia.
    Sung HK; Chan YK; Han M; Jahng JWS; Song E; Danielson E; Berger T; Mak TW; Sweeney G
    J Cell Physiol; 2017 Aug; 232(8):2125-2134. PubMed ID: 27800610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldehyde dehydrogenase 2 ameliorates doxorubicin-induced myocardial dysfunction through detoxification of 4-HNE and suppression of autophagy.
    Sun A; Cheng Y; Zhang Y; Zhang Q; Wang S; Tian S; Zou Y; Hu K; Ren J; Ge J
    J Mol Cell Cardiol; 2014 Jun; 71():92-104. PubMed ID: 24434637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration.
    Abdullah CS; Alam S; Aishwarya R; Miriyala S; Bhuiyan MAN; Panchatcharam M; Pattillo CB; Orr AW; Sadoshima J; Hill JA; Bhuiyan MS
    Sci Rep; 2019 Feb; 9(1):2002. PubMed ID: 30765730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.
    Yokoyama C; Aoyama T; Ido T; Kakino A; Shiraki T; Tanaka T; Nishigaki K; Hasegawa A; Fujita Y; Sawamura T; Minatoguchi S
    PLoS One; 2016; 11(5):e0154994. PubMed ID: 27195769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-12p35 Knock Out Aggravates Doxorubicin-Induced Cardiac Injury and Dysfunction by Aggravating the Inflammatory Response, Oxidative Stress, Apoptosis and Autophagy in Mice.
    Ye J; Huang Y; Que B; Chang C; Liu W; Hu H; Liu L; Shi Y; Wang Y; Wang M; Zeng T; Zhen W; Xu Y; Shi L; Liu J; Jiang H; Ye D; Lin Y; Wan J; Ji Q
    EBioMedicine; 2018 Sep; 35():29-39. PubMed ID: 30228093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IKKα-STAT3-S727 axis: a novel mechanism in DOX-induced cardiomyopathy.
    Chen G; Yao Y; Liu Y; Zhang R; Wen C; Zhou Q; Xu Y; Wang W; Jiang H; Tao Z; Chen W; Qiu Z; Chen X
    Cell Mol Life Sci; 2024 Sep; 81(1):406. PubMed ID: 39287798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nrf2 deficiency exaggerates doxorubicin-induced cardiotoxicity and cardiac dysfunction.
    Li S; Wang W; Niu T; Wang H; Li B; Shao L; Lai Y; Li H; Janicki JS; Wang XL; Tang D; Cui T
    Oxid Med Cell Longev; 2014; 2014():748524. PubMed ID: 24895528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
    van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
    J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipocalin 2 alleviates iron toxicity by facilitating hypoferremia of inflammation and limiting catalytic iron generation.
    Xiao X; Yeoh BS; Saha P; Olvera RA; Singh V; Vijay-Kumar M
    Biometals; 2016 Jun; 29(3):451-65. PubMed ID: 27007712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy.
    Toko H; Oka T; Zou Y; Sakamoto M; Mizukami M; Sano M; Yamamoto R; Sugaya T; Komuro I
    Hypertens Res; 2002 Jul; 25(4):597-603. PubMed ID: 12358147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Congenital absence of nitric oxide synthase 3 potentiates cardiac dysfunction and reduces survival in doxorubicin- and trastuzumab-mediated cardiomyopathy.
    Zeglinski M; Premecz S; Lerner J; Wtorek P; Dasilva M; Hasanally D; Chaudhary R; Sharma A; Thliveris J; Ravandi A; Singal PK; Jassal DS
    Can J Cardiol; 2014 Mar; 30(3):359-67. PubMed ID: 24484915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against doxorubicin-induced myocardial dysfunction in mice by cardiac-specific expression of carboxyl terminus of hsp70-interacting protein.
    Wang L; Zhang TP; Zhang Y; Bi HL; Guan XM; Wang HX; Wang X; Du J; Xia YL; Li HH
    Sci Rep; 2016 Jun; 6():28399. PubMed ID: 27323684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of Nrdp1 in the heart exacerbates doxorubicin-induced cardiac dysfunction in mice.
    Zhang Y; Kang YM; Tian C; Zeng Y; Jia LX; Ma X; Du J; Li HH
    PLoS One; 2011; 6(6):e21104. PubMed ID: 21738612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
    Mohamed HE; Asker ME; Ali SI; el-Fattah TM
    J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction.
    Tian XQ; Ni XW; Xu HL; Zheng L; ZhuGe DL; Chen B; Lu CT; Yuan JJ; Zhao YZ
    Int J Nanomedicine; 2017; 12():7103-7119. PubMed ID: 29026304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice.
    Shizukuda Y; Matoba S; Mian OY; Nguyen T; Hwang PM
    Mol Cell Biochem; 2005 May; 273(1-2):25-32. PubMed ID: 16013437
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Tejera-Muñoz A; Cortés M; Rodriguez-Rodriguez A; Tejedor-Santamaria L; Marchant V; Rayego-Mateos S; Gimeno-Longas MJ; Leask A; Nguyen TQ; Martín M; Tuñón J; Rodríguez I; Ruiz-Ortega M; Rodrigues-Díez RR
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy.
    Kunisada K; Negoro S; Tone E; Funamoto M; Osugi T; Yamada S; Okabe M; Kishimoto T; Yamauchi-Takihara K
    Proc Natl Acad Sci U S A; 2000 Jan; 97(1):315-9. PubMed ID: 10618415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice.
    Nozaki N; Shishido T; Takeishi Y; Kubota I
    Circulation; 2004 Nov; 110(18):2869-74. PubMed ID: 15505089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.